RxDoctor Payments Data

Christopher Pappa, MD

Ophthalmology · Columbus, OHNPI 1689060667

Payments from drug & device makers

$1,745in general payments, 2019–2025

Across 45 payments — averaging $38.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$462
  • AbbVie$446
  • Glaukos Corporation$219
  • Sight Sciences, Inc.$142
  • Aerie Pharmaceuticals, Inc.$124
  • Novartis$119
  • plus $233 from 6 others

What the payments were for

  • Food & beverage$1,745100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,745 in reported general payments places this provider in the 55th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$124,625
Medicare patients
387
Services billed
1,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine26$28,698
LumiganBimatoprost60$21,715
RocklatanNetarsudil Mesylat/Latanoprost33$14,765
CombiganBrimonidine Tartrate/Timolol29$12,679
VyzultaLatanoprostene Bunod24$10,342
Prednisolone Acetate220$8,938
RhopressaNetarsudil Mesylate21$7,188
SimbrinzaBrinzolamide/Brimonidine Tart25$6,669
Cyclosporine16$5,904
Latanoprost777$5,466
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat282$3,883
Timolol Maleate311$3,092
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$2,901
Loteprednol Etabonate16$2,610
Ofloxacin152$1,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$446$63,093115 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$124$21,95354 claims
Bausch & Lomb Americas Inc.Vyzulta$44$10,34224 claims
AlconSimbrinza$462$6,66925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →